Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 6, 1998, Pages 902-912

  Thomas, Chadwick V ^a   McDaniel, George M ^a   Holzgrefe, Henry H ^b   Mukherjee, Rupak ^a   Hird, R Barry ^a   Walker, Jennifer D ^a   Hebbar, Latha ^a   Powell, James R ^b   Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiotensin converting enzyme; Cardiomyopathy; Left ventricular dysfunction; Myocyte contractility; Neutral endopeptidase

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; ENZYME INHIBITION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR AGENTS; DOGS; ENZYME INHIBITORS; FEMALE; HORMONES; MALE; METALLOENDOPEPTIDASES; MYOCARDIAL CONTRACTION; MYOCARDIUM; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; PYRIDINES; RECEPTORS, ADRENERGIC, BETA; THIAZEPINES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031693940     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199812000-00006     Document Type: Article

References (46)

1. Brandt RR, Wright SR, Redfield MM, Burnett JC. Atrial natriuretic peptide in heart failure. J Am Col Cardiol 1993;22:86A-92A.
2. Burnett JC, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145-7.
3. Winaver J, Hoffman A, Abassi Z, Haramati A. Does the heart's hormone, ANP, help in congestive heart failure? News Physiol Sci 1995;10:247-53.
4. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
5. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-51.
6. Kenny AJ, Stephenson SL. Role of endopeptidase 24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett 1988;232:1-8.
7. Seymour AA, Asaad MM, Lanoce VM, Fennell SA, Cheung HS, Rogers WL. Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure. Cardiovasc Res 1993;27:1015-23.
8. Elsner D, Muntze A, Kromer EP, Riegger GA. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-8.
9. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267: 108-16.
10. Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-83.
11. Margulies KB, Barclay PL, Burnett JC. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995;91:2036-42.
12. Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schwartz JC. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction: comparison with captopril. J Pharmacol Exp Ther 1994;270:8-14.
13. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
14. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
15. Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol 1993;22:158A-61.
16. Smith JB, Lincoln TM. Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor. Am J Physiol 1987;253:C147-50.
17. Spinale FG, Holzgrefe HH, Mukherjee R, et al. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation 1995;92:562-78.
18. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during development and regression of supraventricular tachycardia induced cardiomyopathy: disparity between recovery of systolic vs diastolic function. Circulation 1991;83:635-44.
19. Laurenceau JL, Malergue MC. The essentials in echocardiography, M-mode and 2-dimensional imaging. Norwell, MA: Martinus Nijhoff 1981:64-70.
20. Zile MR, Tanaka R, Lindroth JR, Spinale FG, Carabello BA, Mirsky I. Left ventricular volume determined echocardiographically by using a constant LV epicardial long axis to short axis dimension ratio throughout the cardiac cycle. J Am Coll Cardiol 1992;20:986-93.
21. Goldstein DS, Feuerstein G, Izzo HL, Kopin IJ, Keiser H. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 1986;83:265-9.
22. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res 1991;69:1058-67.
23. +-AT-Pase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 1992;24:277-94.
24. Spinale FG, Tempel GE, Mukherjee R, et al. Cellular and molecular alterations in the β-adrenergic system with cardiomyopathy induced by tachycardia. Cardiovasc Res 1994;28:1243-50.
25. Mukherjee F, Hewett K, Crawford FA, Spinale FG. Cell and sarcomere contractile performance from the same cardiocyte using video microscopy. J Appl Physiol 1993;74:2023-33.
26. Spinale FG, Holzgrefe HH, Mukherjee R, et al. Left ventricular and myocyte structure and function with recovery from tachycardia induced cardiomyopathy. Am J Physiol 1995;268:H836-47.
27. Kiuchi K, Shannon RP, Komamura K, et al. Myocardial β-adrenergic receptor function during the development of pacing induced heart failure. J Clin Invest 1993;91:907-14.
28. Roth DA, Kazushi U, Helmer GA, Hammond HK. Downregulation of cardiac guanosine 5′-triphosphate binding proteins in right and left ventricle in pacing induced congestive heart failure. J Clin Invest 1993;91:939-49.
29. Tanaka R, Fulbright BM, Mukherjee R, Burchell SA, Zile MR, Spinale FG. The cellular basis for the blunted response to β-adrenergic stimulation in supraventricular tachycardia induced cardiomyopathy. J Mol Cell Cardiol 1993;25:1215-33.
30. 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
31. Steel RGD, Torrie JH. Principles and procedures of statistics: a biometrical approach. 2nd ed. New York: McGraw-Hill, 1980: 1-623.
32. Poole-Wilson PA. Relation of pathophysiological mechanisms to outcome in heart failure. J Am Coll Cardiol 1993;22:22A-9.
33. Sabbah HN, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
34. 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994;90:3034-46.
35. Weinberg EO, Schoen FJ, George D, et al. Angiotensin converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994;90:1410-22.
36. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16.
37. Willenbrock R, Scheuermann M, Höhnel K, Friedrick CL, Dietz R. Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension 1996;27:1259-66.
38. Jin H, Mathews C, Chen YF, et al. Effects of acute and chronic blockade of neutral endopeptidase with SCH 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats. Am J Hypertens 1992;5:210-8.
39. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994;7: 943-7.
40. Howard RJ, Stopps TP, Moe GW, Gotlieb A, Armstrong PW. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol 1988;66:1505-12.
41. Damiano RJ, Tripp HF, Asano T, Small KW, Jones RH, Lowe JE. Left ventricular dysfunction and dilation resulting from chronic supraventricular tachycardia. J Thorac Cardiovasc Surg 1987;94:135-43.
42. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991;261:H308-18.
43. Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995;92:2306-17.
44. Clemo HF, Baumgarten CM. cGMP and atrial natriuretic factor regulate cell volume of rabbit atrial myocytes. Circ Res 1995;77:741-9.
45. Spinale FG. Pacing tachycardia-induced congestive heart failure. Heart Failure 1995;11:219-32.
46. Lincoln TM. Cyclic CMP: biochemistry, physiology, and pathophysiology. Austin: RG Landes Company, 1994:7-27.